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Type IHsp40s aremolecular chaperones that protect neurons
from degeneration by modulating the aggregation state of amy-
loid-forming proteins. How Type I Hsp40s recognize -rich,
amyloid-like substrates is currently unknown. Thus, we exam-
ined themechanism for binding between the Type I Hsp40 Ydj1
and the yeast prion [RNQ]. Ydj1 recognized the Gln/Asn-rich
prion domain fromRnq1 specifically when it assembled into the
amyloid-like [RNQ] prion state. Upon deletion of YDJ1, over-
expression of the Rnq1 prion domain killed yeast. Surprisingly,
binding and suppression of prion domain toxicity by Ydj1 was
dependent upon farnesylation of its C-terminal CAAX box and
action of a zinc finger-like region. In contrast, folding of lucifer-
ase was independent of farnesylation, yet required the zinc fin-
ger-like region of Ydj1 and a conserved hydrophobic peptide-
binding pocket. Type I Hsp40s contain at least three different
domains thatwork in concert to binddifferent protein conform-
ers. The combined action of a farnesyl moiety and zinc finger-
like region enable Type I Hsp40s to recognize amyloid-like sub-
strates and prevent formation of cytotoxic protein species.
Protein misfolding and aggregation are common themes in
neurodegenerative maladies termed conformational diseases.
A subset of these disorders includingAlzheimer disease and the
transmissible spongiform encephalopathies (prion diseases)
are characterized by the accumulation of stable, -sheet-rich
fibrils called amyloid (1). Criteria that distinguish amyloid-like
fibrils from amorphous aggregates include resistance to SDS
solubilization and binding of the dye thioflavin T (2). The direct
connection between amyloid accumulation and neuropathol-
ogy is still a matter of debate (3–5). Yet, the flux of proteins
through amyloid forming pathways correlates well with disease
(3–5).
Hsp703 molecular chaperones protect against neurodegen-
eration associated with conformational disease via suppression
of protein aggregation or conversion of toxic species into non-
toxic aggregates or amyloid (6, 7). Hsp70 has broad substrate
selectivity and co-chaperones in the Hsp40/DnaJ family specify
Hsp70 targets. Upon delivery of substrate, Hsp40s stimulate
Hsp70 ATPase activity through a conserved J-domain and
thereby stabilize Hsp70polypeptide complexes. Nucleotide
exchange factors convert Hsp70-ADP to Hsp70-ATP releasing
non-native substrate for further rounds of folding or degrada-
tion (8, 9). Escape of disease-related proteins from the action of
Hsp70/Hsp40 and other quality control machinery leads to the
accumulation of toxic protein species (10).
Recognition of pathogenic proteins by Hsp40s represents an
important line of defense against the accumulation of cytotoxic
protein species (4, 11). However, the mechanism for substrate
recognition by Hsp40s is unclear because the Hsp40 family is
large and members have specialized domains that direct them
to different subcellular locations or enable binding to select
substrates (12, 13). Type I Hsp40s possess a centrally located
domain, which contains a zinc finger-like region (ZFLR), that
appears to control the quaternary structure of Type I Hsp40
homodimers (14). The ZFLR has been implicated in substrate
transfer to Hsp70 and the binding of some Type I Hsp40 sub-
strates (15–17). Type I Hsp40s can independently bind non-
native polypeptides and also cooperate with Hsp70 to suppress
protein aggregation (18, 19). Importantly, human and yeast
Type I Hsp40s are highly conserved and functionally inter-
changeable (12).
Interestingly, Type I Hsp40s such as human DnaJ 2 (HDJ-2)
and yeast DnaJ 1 (Ydj1) are unique in that they contain a C-ter-
minal CAAX box that is post-translationally modified by farne-
syl (20, 21). Farnesylation helps localize a pool of Type I Hsp40s
to the cytoplasmic face of the endoplasmic reticulum and is
required for cells to survive heat stress (22). One function of
endoplasmic reticulum-localized Type I Hsp40s is the folding
of polytopic membrane proteins (21). However, even though
the entire pool of Ydj1 is farnesylated a large portion is found in
the cytosol (22). Thus, it is conceivable that the farnesyl moiety
of Ydj1/Hdj-2 has additional roles in cytoprotection including
regulation of stress response or assistance with polypeptide
binding.
Study of Hsp40 action in propagation of the yeast prion
[RNQ]/[PIN] (23, 24) provides a tractable model system to
answer basic questions aboutmechanisms for chaperone action
in the suppression of proteotoxicity. Overexpression of Rnq1
kills yeast in the presence of [RNQ] seeds, yet toxicity is asso-
ciated with the accumulation of off-pathway, non-amyloid
forms of Rnq1 (4). Rnq1 has an N-terminal non-prion domain
with no known enzymatic function although it appears to reg-
ulate the conversion of native Rnq1 into the [RNQ] prion (25).
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Rnq1 also possesses a C-terminal prion domain (PrD) that is
enriched in glutamines (Gln) and asparagines (Asn) and readily
assembles into the [RNQ] prion state when expressed alone or
as a chimera (23, 26). Interestingly, the Type II Hsp40 Sis1 is
required for [RNQ] propagation (27) and suppresses Rnq1
toxicity via increasing the flux of Rnq1 into the [RNQ] assem-
bly pathway (4). On the other hand, the Type I Hsp40 Ydj1 can
cure yeast of some [RNQ] variants (28), but it cannot suppress
Rnq1 cytotoxicity (4). Although Sis1 binds a hydrophobicmotif
in the Rnq1 non-prion domain (4) the Ydj1-binding site is
unknown (29). Because Ydj1 and Sis1 show distinct substrate
selectivity (13) we investigated whether they exert their dispar-
ate effects on Rnq1 biogenesis and toxicity via binding different
Rnq1 domains.
We found that purified Ydj1 recognizes Gln/Asn-rich pep-
tides in the PrD of Rnq1. In in vivo studies, Ydj1 specifically
recognized the amyloid-like [RNQ] form of the Gln/Asn-rich
Rnq1 PrD. Furthermore, deletion of YDJ1 sensitized yeast to
excess levels of the PrD. Interestingly, Ydj1 binding and sup-
pression of toxicity was dependent upon both the Type I Hsp40
ZFLR and farnesylation. On the other hand, the ZFLR and pep-
tide-binding pocket cooperated in the folding of luciferase,
whereas farnesylation of Ydj1 was dispensable in this activity.
Thus,Type IHsp40sutilize specializeddomains to recognizenon-
native proteins that exist in different conformational states. Dem-
onstration of the domain requirements for Ydj1 binding to the
amyloid-like conformer of the Rnq1 helps explain how human
Type I Hsp40s fight conformational disease.
EXPERIMENTAL PROCEDURES
Yeast Strains and Plasmids—All experiments were con-
ducted in the yeast strain BY4741 (MATa his3, leu2,
met15, ura3) in a wild type, ydj1 (ydj1::KAN1), or ram1
(ram1:KAN1) background. Yeast strains were cured of prion
seeds by three sequential passages on YPD media containing 3
mM guanidine HCl. Ydj1 wild type andmutant constructs were
expressed from the endogenous YDJ1 promoter in a pRS315
plasmid backbone (15). The YDJ1 open reading frame was also
subcloned into a pRS315 backbone behind a glyceraldehyde-
phosphate dehydrogenase promoter. The prion domain of
Rnq1 (PrD: amino acids 153–405) was generated by PCR
amplification of nucleotides 459–1215 from RNQ1 and sub-
cloned in a pRS416 backbone behind the GAL1 promoter or
into a pRS316 backbone behind the CUP1 promoter with a
green fluorescent protein tag at the C terminus. Sup35 was
amplified from genomic DNA and inserted downstream of the
CUP1 promoter and upstream of a green fluorescent protein
tag in a pRS416 background. Point mutants were generated
using a Stratagene QuikChange mutagenesis kit. Yeast strains
were generated by transformation using the lithium acetate
method and selected on synthetic minimal media supple-
mented with amino acids required for survival.
Cell Viability Assay—Freshly transformed cells harboring
pRS416-RNQ1 or PrD with the indicated version of YDJ1 were
serially diluted on minimal selection media containing 2%
galactose or 2% glucose. Plates were incubated at 30 °C for 3–4
days and photographed.
Fluorescence Microscopy—Cells transformed with Rnq1-
GFP or PrD-GFP under the control of theCUP1 promoter were
induced with 50 M CuSO4 for 2 h, then mounted on a glass
slide and visualized with a Nikon Eclipse E600 fluorescence
microscope.
Differential Centrifugation—Yeast cells were grown to mid-
log phase and Rnq1-GFP or PrD-GFP induced for 4 h with 50
M CuSO4. Cells were lysed in Buffer A (50 mM Hepes, pH 7.4,
150 mM NaCl, 0.1% Triton X-100, 1 mM phenylmethylsulfonyl
fluoride, 1 protease inhibitor mixture (Roche Applied Sci-
ence)) with glass beads in 30-s intervals for 8 cycles. Crude
lysates were cleared of cell debris at 3000  g for 3 min. About
100 g of protein extract was subjected to high-speed centrif-
ugation (100,00  g) in a Beckman Type 70Ti rotor for 30 min.
Supernatant and pellet fractionswere resolvedwith input (10%)
by SDS-PAGE and assessed by Western immunoblotting.
Gel Filtration—Yeast cells were grown and lysed in Buffer A
as described above. About 5 mg of protein extract was applied
to a Sephacryl S-500HR gel filtration column (GE Healthcare).
The column was calibrated with molecular weight markers
from Amersham. Every other fraction was loaded on an acryl-
amide gel and analyzed by SDS-PAGE.
Rnq1 Peptide Array—A Rnq1 25-mer peptide array from
Jenri Peptide Technologies was screened with purified Ydj1
according to the manufacturer’s instructions and as previously
described (4).
Co-immunoprecipitation—Rnq1-GFP or PrD-GFP were
induced in wild type or ydj1 cells expressing the indicated
form of Ydj1 as described above. Cell lysates were prepared in
Buffer A as described above. Ydj1 was co-immunoprecipitated
from about 100 g of protein extract using Ydj1 polyclonal
antisera and protein G-agarose beads (Roche) with standard
techniques. Bound protein was analyzed by SDS-PAGE with
10% original lysate representing input.
Filter Trap Assay—PrD-GFP was induced and cells were
lysed in Buffer A as described above. Approximately 20 g of
protein extract was added to sample buffer (2% SDS, 62.5 mM
Tris-HCl, pH 6.8, 1mMEDTA, 5% glycerol, 2%-mercaptoeth-
anol) then loaded onto a cellulose acetatemembrane assembled
in a slot blot apparatus. The membrane was washed in 0.1%
SDS and retained PrD-GFP assessed by immunoblotting for
GFP (Roche). Lysates were also analyzed by SDS-PAGE to
determine protein expression levels. Western immunoblot-
ting for 3-phosphoglycerate kinase (Molecular Probes) was
used as a load control.
Luciferase Reporter Assay—Yeast cells harboring firefly lucif-
erase on a galactose-inducible promoter and the indicated ver-
sion ofYDJ1were grown tomid-log phasewith 2% raffinose and
luciferase induced with 2% galactose. Luciferase activity was
measured as previously described (30) with a TD 20/20 lumi-
nometer. For in vitro luciferase refolding assays, firefly lucifer-
ase was purified and refolding measured as previously
described (15). A two sampled t test (assuming unequal vari-
ances)was used to generate p values comparing luciferase activ-
ity between wild type and mutant Ydj1.
Reconstitution of Chaperone-dependent Polyubiquitination—
Recombinant chaperones were purified and experimental con-
Ydj1 Action in Prion Toxicity
FEBRUARY 6, 2009 • VOLUME 284 • NUMBER 6 JOURNAL OF BIOLOGICAL CHEMISTRY 3629
ditions were conducted as previously described (31) substitut-
ing recombinant Ydj1 or the mutant as the Hsp40.
RESULTS
The Rnq1 PrD Forms Benign Intracellular Aggregates—Over-
expression of Rnq1 is toxic to yeast when endogenous Rnq1 is
assembled in its [RNQ] conformation (4). Cell death is
thought to occur due to inefficient conversion of overexpressed
Rnq1 into amyloid-like [RNQ] prions and the accumulation of
a templated toxic species. Furthermore, defects in Sis1-binding
exacerbate Rnq1 toxicity by decreasing the efficiency of
[RNQ] assembly. The nature of the toxic Rnq1 species is not
clear and how defects in chaperone binding lead to its accumu-
lation are unknown. Thus, we investigated whether removal of
the entire non-prion domain and elimination of the Sis1 bind-
ing site would enhance Rnq1 proteotoxicity. Whereas overex-
pression of Rnq1 was toxic to [RNQ] cells, overexpression of
the PrD was not (Fig. 1, A and B). Overexpression of Rnq1 or
PrD did not alter cell growth in the absence of prion seeds
([rnq] background). Thus, the presence of the non-prion
domain on Rnq1 somehow leads to the accumulation of a toxic
Rnq1 species.
To gain insight into the nature of the toxic Rnq1 species we
characterized intermediates on the pathway for conversion of
native Rnq1 and PrD into amyloid-like [RNQ] prion. Rnq1-
GFP and PrD-GFP each formed intracellular aggregates in a
[RNQ] background that were morphologically indistinguish-
able by fluorescence microscopy (Fig. 1C). Rnq1 was not
observed to coalesce in a [rnq] background although a small
population of cells (5%) expressing PrD-GFP contained non-
toxic aggregates. In a [RNQ] background, Rnq1-GFP parti-
tioned predominantly in the Triton-insoluble pellet of yeast
extracts, although a significant population was present in the
Triton-soluble supernatant (Fig. 1C). In contrast, PrD-GFP
fractionated exclusively in the Triton-insoluble pellet in a
[RNQ] background. In a [rnq] state, Rnq1-GFPwas predom-
inantly soluble, whereas PrD-GFP was present in both Triton-
soluble and -insoluble fractions. The PrD appears more prone
to nonspecific aggregation, but such aggregates do not appear
toxic.
Next, the size of Rnq1-GFP and PrD-GFP assembly interme-
diates was examined by gel filtration chromatography (Fig. 1E).
In [RNQ] cells, Rnq1-GFP eluted in two distinct high molec-
ular pools; one near the void volume (Vo) and the other in a
broad peak that was larger than thyroglobulin (669 kDa), but
still in the included volume. In addition, a pool of Rnq1-GFP
eluted similar to a monomeric form. PrD-GFP also formed two
high molecular weight pools, yet in contrast to Rnq1; no low
molecular weight species was detected. Thematerial in the void
volume was predominantly SDS-soluble, whereas Rnq1/PrD-
GFP species in the included broad peak were insoluble in SDS
(data not shown). In a [rnq] background, Rnq1-GFP resided
exclusively in the lowmolecular weight pool, whereas PrD-GFP
eluted in the void volume as well as a lowmolecular weight pool
(Fig. 1E).
These observations suggest deletion of the non-prion
domain predisposes the PrD to spontaneous aggregation in
either a [RNQ] or [rnq] background. However, PrD aggre-
gates in a [rnq] background are not amyloid-like because the
PrD only forms thioflavin T-positive, SDS-resistant aggregates
in a [RNQ] background (supplemental Fig. S1). Thus, the
presence of the non-prion domain predisposes a small portion
of Rnq1 to accumulate in a soluble pool, which could result
from inefficient assembly or increased shearing of [RNQ] pri-
ons into [RNQ] seeds by Hsp104 (27). Observations that PrD
overexpression is not toxic and its assembly into amyloid-like
prions is not accompanied by the accumulation of a soluble PrD
pool supports the notion that accumulation of soluble Rnq1 in
a [RNQ] background leads to death (4).
Ydj1 Binds the Gln/Asn-rich PrD in Its [RNQ] Conforma-
tion—Deletion of the Rnq1 non-prion domain and the Sis1-
binding motif (4), renders the PrD prone to form benign aggre-
gates in [RNQ] and [rnq] cells. The combined ability of the
cell to package the PrD into amyloid-like assemblies as well as
SDS-sensitive aggregates may account for the benign conse-
quences of PrD overexpression. Chaperones facilitate the for-
mation of benign, non-amyloid aggregates of A-(1–42) (32).
Therefore, we speculated that an Hsp40 other than Sis1 may
recognize the Gln/Asn-rich PrD and prevent the formation of a
toxic PrD species by facilitating the conversion of soluble, unas-
sembled PrD species into benign SDS-sensitive aggregates.
The Type I Hsp40 Ydj1 binds Rnq1 (29), so it may modulate
PrD assembly. To identify the Ydj1 binding site in Rnq1, we
screened a Rnq1 peptide array with purified Ydj1 (Fig. 2, A and
B). Each peptide in the array was 25 amino acids in length and
shared 22 amino acids with the adjacent peptide such that small
binding motifs could be identified. Ydj1 bound numerous pep-
tides from the PrD, but no peptides from the non-prion domain
(Fig. 2B). Ydj1 bound peptides that were typically composed of
Gln/Asn-rich motifs interrupted by aliphatic or aromatic resi-
dues (Fig. 2B). These hydrophobic residues may facilitate bind-
ing with the Ydj1 hydrophobic peptide-binding pocket (33).
Consistent with this possibility, Ydj1 did not bind a glutamine/
glycine repeat at the beginning of the PrD. However, numerous
hydrophobic residues are present in the non-prion domain and
the terminal 50 amino acids of Rnq1 that were not bound by
Ydj1. As such, the arrangement of Gln and Asn amino acids
along with hydrophobic residues appears critical for Ydj1 to
specifically recognize PrD peptides.
Ydj1 binds proteins with polyglutamine repeats in a manner
that is dependent upon the expansion length and regulates their
assembly into higher order aggregates (34, 35). Thus, Ydj1 may
be able to recognize substrates enriched in -structure. To
address whether conversion of Rnq1 or the PrD into a -rich
conformation is required for Ydj1 binding, we assessed the
interaction of Ydj1 with the native or amyloid-like prion forms
of Rnq1 and the PrD. Ydj1 co-immunoprecipitated Rnq1-GFP
and PrD-GFP from [RNQ] lysates, yet not from [rnq] lysates
suggesting Ydj1 prefers the [RNQ] prion conformation of
these proteins (Fig. 2C). In addition, Ydj1 did not co-immuno-
precipitate the non-prion domain alone and the PrDwas a poor
substrate for Sis1 in [RNQ] lysates (supplemental Fig. S2). The
PrD from Rnq1 assembles into thioflavin T-positive, amyloid-
like fibrils (36, 37). Therefore Ydj1, but not Sis1, recognizes the
PrD of Rnq1 in its -sheet rich, amyloid-like conformation.
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Overexpressing the PrD Is Toxic to Yeast in the Absence of
YDJ1—If Ydj1 binds the PrD in its amyloid-like conformation,
then Ydj1 may act analogous to Sis1 in suppressing Rnq1 tox-
icity by facilitating assembly of the PrD into a benign confor-
mation. To test this hypothesis, the PrD was overexpressed in a
ydj1 strain that contains pre-existing [RNQ] prions. Indeed,
PrD overexpression was highly toxic to yeast in a ydj1 back-
ground (Fig. 3A). Cell viability was rescued by Ydj1 expression
FIGURE 1. The Rnq1 PrD assembles into benign [RNQ] prion. A, domain boundaries of Rnq1 from Saccharomyces cerevisiae. B, wild type yeast in a [RNQ] or [rnq]
background harboring galactose-inducible forms of Rnq1, PrD, or an empty vector were serially diluted onto media containing galactose or glucose. Western blots
below show protein levels. C, fluorescence microscopy of representative cells expressing Rnq1-GFP or PrD-GFP in a [RNQ] or [rnq] background. D, differential
centrifugation of Rnq1-GFP and PrD-GFP in a [RNQ] or [rnq] background. Briefly, cell lysates were generated under non-denaturing conditions (50 mM Hepes, pH 7.4,
150 mM NaCl, 0.1% Triton X-100, 1 mM EDTA) and separated by high-speed centrifugation (100,000  g). Total input (T), supernatant (S), and pellet (P) fractions were
resolved by SDS-PAGE. E, yeast lysates generated as above under nondenaturing conditions were resolved on a Sephacryl S-500HR gel filtration column. Every other
fraction was examined by SDS-PAGE. Below is quantification of fractions normalized to total signal from [RNQ] lysates (left graph) or [rnq] lysates (right graph).
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from a low copy plasmid from its own promoter. Even though
PrD expression from the GAL1 promoter was toxic, PrD pro-
tein levels were much lower in the ydj1 strain compared with
the YDJ1-rescued strain (Fig. 3A, lower panel). This was not sur-
prising becauseYDJ1 is required for efficient nucleosomal remod-
eling and activation of theGAL1 promoter (38).
In contrast to what is observed with [RNQ] assembly
when Sis1 is depleted (4, 27), the PrD still formed intracel-
lular aggregates and did not accumulate as a soluble species
when Ydj1 was deleted (Fig. 3, B–D). In fact, the only differ-
ence we observed was a close to 2-fold increase in the levels
of SDS-resistant PrD-GFP in the ydj1 strain compared with
wild type background (Fig. 3E). Therefore, Ydj1 appears to
enable yeast to tolerate PrD expression by limiting the pool
of amyloid-like PrD assemblies. Consistent with this hypoth-
esis, overexpression of Ydj1 decreased the level SDS-resist-
ant PrD-GFP (Fig. 3F). Thus, PrD toxicity appears to differ
from Rnq1 toxicity in that the
accumulation of SDS-resistant
forms of PrD, and not a lowmolec-
ular weight, detergent-soluble
species correlates with cell death.
The mechanism via which Ydj1
modulates the accumulation of
SDS-resistant PrD and suppresses
PrD toxicity is unclear. Ydj1 may
cap the exposed ends of elongating
PrD amyloid or interact with
Hsp104 (39) to maintain the level of
this species within a tolerable range.
Alternatively, Ydj1 may coat PrD
particles to prevent nonspecific pro-
tein-protein interactions that titrate
essential cellular factors. We favor
the former model because whereas
Ydj1 co-immunoprecipitates with
PrD-GFP we did not observe a large
pool of Ydj1 co-migratingwith PrD-
GFP on gel filtration columns.
Instead, Ydj1 eluted in a broad peak
higher than the predictedmolecular
mass for a Ydj1 homodimer (90
kDa). This may occur because Ydj1
forms complexes with an array of
different cellular proteins. In addi-
tion, Ydj1 is farnesylated and this
post-translationalmodificationmay
lead it to behave like a proteinwith a
higher molecular weight in gel fil-
tration analysis.Nevertheless, only a
small pool of Ydj1 binds and co-mi-
grates with PrD prions and this does
not seem sufficient to serve a coat-
ing function.
Mutation of the CAAX Box Pre-
vents Ydj1 from Suppressing PrD
Toxicity—The ability of Ydj1 to spe-
cifically recognize the Gln/Asn-rich
PrD was surprising because numerous studies suggest Type I
Hsp40s prefer peptides enriched in hydrophobic amino acids
(13, 40). Thus, we investigated the structural features in Ydj1
that enable it to bind andmodulate PrD toxicity. First, we dem-
onstrated that Sis1 could not suppress the toxicity observed
when PrD was overexpressed and the ydj1 strain (data not
shown). Then we sought to define the minimal length of Ydj1
required to suppress PrD toxicity (Fig. 4A). The ydj1 strain
normally exhibits a slow growth phenotype (20) and the Ydj1
J-domain and G/F-rich region can restore normal growth in a
ydj1 strain (41). Yet, this same Ydj1 fragment could not sup-
press PrD toxicity (Fig. 4B). Although the Ydj1 J-domain was
not sufficient to suppress PrD toxicity, an active J-domain was
still necessary because mutation in the conserved HPD tripep-
tide motif (H34Q) that severely disrupts interaction between
Ydj1 andHsp70 (42) rendered yeast unable to tolerate PrD tox-
icity (supplemental Fig. S3A). Binding between PrD-GFP and
FIGURE 2. Ydj1 interacts with the PrD of Rnq1. A, Rnq1 amino acid sequence from S. cerevisiae. Residues in the
PrD of Rnq1 are highlighted. B, a 25-amino acid peptide array from Rnq1 was screened with purified Ydj1.
Peptides bound by Ydj1 are highlighted. The intensity of the highlight designates relative binding as assessed
by immunoblotting for Ydj1. Three sample peptides from the PrD that were recognized by Ydj1 are listed
below. C, Rnq1-GFP or PrD-GFP were expressed in wild type yeast in a [RNQ] or [rnq] background and cell
lysates were generated under nondenaturing conditions. Ydj1 was co-immunoprecipitated and bound Rnq1-
GFP or PrD-GFP was assessed by Western immunoblotting for GFP (right panel). The same lysates were incu-
bated in the absence of Ydj1 antisera to show background binding to Protein G beads (ab). Expression
levels from whole cell lysates represent 10% input (left panel).
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Ydj1(H34Q) was only slightly reduced (74% of wild type) and
the levels of SDS-resistant PrD-GFP were increased with
Ydj1(H34Q) compared with wild type (supplemental Fig. S3, B
and C). Altogether, these observations suggest functional fea-
tures of Ydj1 that support normal growth are less complex than
those required to suppress PrD toxicity.
FIGURE 3. Deletion of YDJ1 sensitizes yeast to overexpression of the PrD. A, cells in a ydj1 strain ([RNQ] background) were transformed with an empty pRS315
plasmid or a pRS315 plasmid expressing Ydj1 from the YDJ1 promoter. These strains were further transformed with plasmids harboring galactose-inducible PrD or
empty plasmid (pRS416). These cells were serially diluted onto selective media containing galactose or glucose. Western blots below show protein expression levels.
B, fluorescence microscopy of representative cells expressing PrD-GFP in the presence or absence of Ydj1. C, differential centrifugation as performed as described in
the legend to Fig. 1 of cell lysates from strains expressing PrD-GFP in the presence or absence of Ydj1 (right panel: supernatant (S) and pellet (P)). Left panel shows protein
levels from whole cell lysates. D, gel filtration analysis of PrD-GFP in the presence or absence of Ydj1 as described in the legend to Fig. 1. Fractions from a YDJ1-rescued
strain were also assessed for Ydj1 distribution. Below is quantification of PrD-GFP levels in every other fraction normalized to total PrD-GFP. E, the assembly of
SDS-resistant PrD-GFP was determined by filter trap analysis. PrD-GFP was induced in the presence or absence of Ydj1 and cells were lysed under denaturing
conditions (2% SDS, 62.5 mM Tris-HCl, pH 6.8, 1 mM EDTA, 5% glycerol, 2% -mercaptoethanol). Lysates were applied to a cellulose acetate filter and retained PrD-GFP
was assessed by Western (WB) immunoblotting for GFP. F, levels of SDS-resistant PrD-GFP were also determined in the presence of overexpressed Ydj1. Wild type yeast
harboring an empty vector (pRS315) or YDJ1 under the control of a constitutively active promoter (GPD) expressing PrD-GFP were lysed as described in E and lysates
analyzed by filter trap. Panels below show protein levels from cell lysates used in filter trap assay.
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Ydj1-(1–336) contains the J-domain, G/F-rich region, ZFLR,
and a polypeptide-binding pocket, yet the Ydj1 dimerization
domain is severed (43) and a CAAXmotif required for farnesy-
lation is missing (22). Ydj1 fragments with similar domain
structures bind non-native polypeptides and suppress protein
aggregation (44). Expression of Ydj1-(1–336) in the ydj1
strain restored normal growth, but barely protected against
PrD toxicity (Fig. 4B). To determine whether dimerization
and/or farnesylation are required for complete suppression of
PrD toxicity, specific point mutants in the extreme Ydj1 C ter-
minus were examined. Ydj1(F335D), which contains point
mutation in the dimerization domain that monomerizes Ydj1
(data not shown) (43), suppressed PrD toxicity as well as wild
type, suggesting the Ydj1 monomer is sufficient in this activity.
However, mutation of the CAAX box (C406S) eliminated the
ability of Ydj1 to suppress PrD toxicity (Fig. 4B).
These data were surprising because farnesylation is thought
to be required formembrane localization of Ydj1 yet PrDprions
appear cytosolic. Thus, we investigatedwhether farnesylation is
required for Ydj1 to bind the amyloid-like form of the PrD.
Indeed, we observed an 80% reduction in complex formation
between Ydj1(C406S) and the PrD (Fig. 4C). However, the
pool of SDS-insoluble PrD-GFP was not increased with
Ydj1(C406S) compared with wild type (Fig. 4D). The residual
binding between Ydj1(C406S) and the PrD may be sufficient
to control the accumulation of SDS-insoluble aggregates:
although farnesylation of Ydj1 was clearly required for tol-
erance of PrD overexpression.
To demonstrate that defects in Ydj1(C406S) function were
indeed due to the lack farnesylation, the PrDwas expressed in a
ram1 strain, in which a non-essential farnesyltransferase sub-
unit was deleted. In this strain background Ydj1 is not farnesyl-
ated (44) and overexpression of the PrD is toxic (supplemental
Fig. S4). In addition, interactions between Ydj1 and the PrD in
the ram1 strain were reduced. Thus, defects in the ability of
Ydj1(C406S) to suppress PrD toxicity are indeed due to loss of
farnesylation. These data provide the first evidence for a role
of a farnesylmoiety on aType IHsp40 in binding to an amyloid-
like substrate and in suppression of prion toxicity.
The ZFLR Is Required to Bind the PrD and Suppress Toxicity—
Because Ydj1(C406S) could still control levels of amyloid-like
PrDprions, we explored the role for theType IHsp40ZFLR (17,
33) in complex formation between Ydj1 and the PrD (Fig. 5A).
Point mutations in individual zinc-binding domains (ZBDs) of
Ydj1 were tested for their effect on suppression of PrD toxicity.
Mutation of ZBD1 (C143S or C201S) had no effect on themod-
ulation on Ydj1 of PrD toxicity (Fig. 5B). However, mutation of
ZBDII (C162S or C185S) dramatically disrupted the ability of
Ydj1 to suppress PrD toxicity. Thus, ZBDII of Ydj1 is required
FIGURE 4. The Ydj1 CAAX box is required to suppress PrD toxicity.
A, domain structure of Ydj1 and truncations used in this study. B, truncations
and mutants were expressed in a pRS315 (low copy) plasmid under control of
the YDJ1 promoter in a ydj1 background. These cells, harboring a plasmid
expressing the PrD on a galactose-inducible promoter, were serially diluted
onto media containing galactose and grown at 30 °C. These cells were also
serially diluted onto media containing glucose and grown at 30 or 33 °C.
C, binding between Ydj1 or Ydj1(C406S) with PrD-GFP was assessed by co-
immunoprecipitation with Ydj1 antisera. PrD-GFP levels in the ydj1 strain
(pRS315) represent background binding to the Protein G beads. Percentages
below represent bound PrD-GFP levels as a percentage of wild type Ydj1
normalized to background. D, SDS-resistant PrD-GFP was compared in a
ydj1, Ydj1, or Ydj1(C406S) background by filter trap. Panels below show pro-
tein levels from cell lysates. WB, Western blot.
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for yeast to tolerate overexpression
of the PrD. Defects in cytoprotec-
tion by Ydj1 ZBDII mutants corre-
lated with a substantial 90%
decrease binding between PrD-GFP
and Ydj1(C162S) (Fig. 5C). Further-
more, the pool of SDS-insoluble
PrD-GFP was increased in the pres-
ence of Ydj1(C162S) to levels
observed in the ydj1 strain (Fig.
5D). We found these data interest-
ing because we knew that ZBDII is
required for the protein folding
function of Ydj1, but action of the
ZFLR appeared dispensable for
binding globular proteins (15, 16,
45). Thus, the data presented iden-
tify a critical role for the Type I
Hsp40 ZFLR in binding and sup-
pressing the toxicity of proteins that
form amyloid-like aggregates.
Ydj1 contains a hydrophobic
depression in C-terminal domain 1
(CTD1) that is required for folding
model proteins, is conserved in
Type II Hsp40s, and has been co-
crystallized in a complex with a
hydrophobic peptide (33). Because
Ydj1 bound peptides in the PrD that
contained hydrophobic peptides
(Fig. 2), the role of CTD1 in sup-
pression of prion toxicity was inves-
tigated. To address whether the
peptide-binding pocket of Ydj1 par-
ticipates in PrD binding, several sol-
vent-exposed hydrophobic residues
in this groove were mutated (Fig.
5E). Point mutations in this pocket
disrupt binding and refolding of
luciferase in vitro (46). However,
Ydj1 peptide-binding pocket mu-
tants were capable of suppress-
ing PrD toxicity (Fig. 5F). PrD
expression was slightly toxic in
strains that harbored Ydj1(L135S).
Yet, Ydj1(L135S) bound PrD-GFP
almost as well as wild type Ydj1 and
no increase in SDS-insoluble PrD-
GFP was observed in this mutant
background (Fig. 5,G andH). Thus,
when peptide binding by CTD1 is
compromised through mutation,
actions of the ZFLR and farnesyl
moiety on Ydj1 appear sufficient for
modulation of PrD toxicity.
At this point we want to note that
the role of the ZFLR of Ydj1 and far-
nesyl moiety in binding to amyloid-
FIGURE 5. Mutation in the Ydj1 ZFLR disrupts binding to the PrD. A, ribbon diagram of the x-ray crystal
structure from Ydj1-(110 –337). Zinc binding domains in the Ydj1 ZFLR are noted as well as the peptide-binding
pocket. B, cells from a ydj1 background were transformed with pRS315 (low copy) plasmids expressing wild
type Ydj1 or the indicated ZFLR mutant from the YDJ1 promoter. These cells, also harboring a plasmid express-
ing PrD from a galactose-inducible promoter, were serially diluted onto selective media containing galactose
or glucose. C, binding between PrD-GFP and the indicated form of Ydj1 was assessed by co-immunoprecipi-
tation with Ydj1 antisera. Percentages below represent bound PrD-GFP levels as a percentage of wild type
Ydj1 normalized to background (pRS315). D, SDS-resistant PrD-GFP was compared between a ydj1, Ydj1,
Ydj1(C162S) background by filter trap. E, PyMOL model of the Ydj1 peptide-binding pocket (hydrophobic, red;
basic, blue; acidic, yellow). Specific residues examined in this study are identified. F, strains from a ydj1 back-
ground were transformed as described above with plasmids expressing wild type Ydj1 or the indicated
polypeptide-binding mutant. These cells, also expressing galactose-inducible PrD, were serially diluted onto
media containing galactose or glucose. G, binding between PrD-GFP and the indicated form of Ydj1 was
assessed by co-immunoprecipitation with Ydj1 antisera as above. H, SDS-resistant PrD-GFP was compared
between a ydj1, Ydj1, and Ydj1(L135S) background by filter trap. For filter trap assays, panels below show
protein expression levels from cell lysates. WB, Western blot.
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like prion protein conformers is not limited to the PrD of Rnq1.
Ydj1 binding to the prion formof the yeast prion Sup35was also
severely disrupted by mutation of ZBDII in the ZFLR and
reduced by mutation of the CAAX box (supplemental Fig. S5).
Thus, conserved domains that are found in Type I Hsp40s
enable Ydj1 to bind proteins that assume amyloid-like states.
Structural Requirements for Ydj1 Binding to HD53Q—The
above observations suggest the Ydj1 ZFLR participates in rec-
ognition of -rich, amyloid-like substrates and that it may or
may not require assistance of CTD1. To determine the gener-
ality of the data obtained in study of the PrD, we examined
structural requirements for Ydj1 binding to a purified hunting-
tin fragment that contains exon 1 and a Gln53 expansion
(HD53Q) (47). Although wild type Ydj1 suppressed HD53Q
aggregation in a dose-dependent manner, Ydj1(C162S) was
almost entirely defective (supplemental Fig. S6). Interestingly,
Ydj1(I215S), which contains a point mutation in the peptide-
binding pocket, was also inactive in suppressing HD53Q aggre-
gation. Ile215 is located at the base of the Ydj1 polypeptide-
binding pocket and may be required to stabilize this groove,
although Ydj1(I215S) could still suppress PrD toxicity suggest-
ing it is not grossly misfolded. HD53Q includes a 17-residue
peptide from exon 1 of human huntingtin that contains several
hydrophobic motifs. Thus, we propose that Ydj1 utilizes a
bipartite mechanism to suppress HD53Q aggregation in which
-strands in the ZFLR interact with the poly(Q) expansion and
solvent-exposed residues in the hydrophobic pocket interact
with the exon 1 peptide. However, it was difficult to test this
hypothesis because Ydj1(C162S) and Ydj1(I215S) were almost
entirely inactive. Nevertheless, function of both the ZFLR and
CTD1 are required for Ydj1 to suppress HD53Q aggregation.
The Ydj1 ZFLR and Peptide-binding Pocket Regulate Lucifer-
ase Refolding in Vivo—Data presented thus far suggest that
Type I Hsp40s contain at least three domains that are required
for interaction of Ydj1 with non-native substrates, yet the
requirements of each are substrate-dependent. To test this
model we compared the structural requirements for the action
of Ydj1 in suppression of PrD biogenesis to those for in vivo and
in vitro folding of the globular protein luciferase. Luciferasewas
expressed from the GAL1 promoter in aydj1 strain harboring
Ydj1 mutants discussed above. Minimal luciferase activity was
observed in the ydj1 strain, although very little luciferase was
expressed from theGAL1 promoter (Fig. 6,A and B).Wild type
Ydj1 restored luciferase expression and activity. However,
mutation of either ZBDI or ZBDII severely reduced luciferase
activity even though luciferase expression levelswere recovered
to near wild type. Ydj1(C162S) still bound luciferase (data not
shown) suggesting this defect reflects an inability of Ydj1 to
maintain luciferase in a conformation that subsequently is
bound by Hsp70 (15). Ydj1(L135S) and Ydj1(I215S) only sup-
ported luciferase activity at around 50% of wild type levels.
Interestingly, Ydj1(C406S) supported luciferase expression and
activity to near wild type levels. Thus, farnesylation of Ydj1 is
dispensable for in vivo folding of luciferase.
Defects exhibited byYdj1mutantswith in vivo assays of lucif-
erase refolding were recapitulated when activity of the purified
forms of these proteins were monitored with in vitro luciferase
refolding assays (Fig. 6C). The ability of Ydj1 to promote
expression and folding of luciferase requires the ZFLR and
CTD1, yet this process occurs when the CAAX box is not
farnesylated.
The Ydj1 ZFLR and Peptide-binding Pocket Cooperate in
Chaperone-dependent Polyubiquitination—Crystal structures
demonstrate that the ZFLR and CTD1 are in close proximity to
each other (33) and these domains appear to cooperate in the
process of suppressing HD53Q aggregation. To further study
this issue we examined the contribution of the Ydj1 ZFLR and
FIGURE 6. Mutations in the Ydj1 ZFLR and peptide-binding pocket dis-
rupt luciferase refolding in vivo. A, firefly luciferase was expressed in a ydj1
strain harboring the indicated form of Ydj1 expressed from a pRS315 plasmid
under control of the YDJ1 promoter. Luciferase activity was measured in
intact cells with a luminometer. Luciferase activity is represented as percent
of control (wild type Ydj1). B, expression of firefly luciferase in yeast in the
presence of the indicated form of Ydj1. Cell lysates were analyzed by SDS-
PAGE and assessed by Western (WB) immunoblotting for luciferase and Ydj1.
C, luciferase activity was also assessed in vitro. Purified firefly luciferase (50 nM)
was incubated with Hsp70 (0.5 M) and the indicated form of Ydj1 (1 M). Error
bars represent S.E. from three independent trials (*, p  0.01; **, p  0.001).
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peptide-binding pocket in chaperone-dependent polyubiquiti-
nation reactions (31). Purified Ydj1 was incubated with Hsp70,
the E2 UbcH5a and E3 ubiquitin ligase CHIP to assess polyu-
biquitination of a model GST fusion (GST-NBD1-R, which
contains nucleotide binding domain 1 and the regulatory
domain from cystic fibrosis transmembrane regulator) (31). In
the absence of Ydj1 little ubiquitination of GST-NBD1-R was
observed. Yet, upon addition of Ydj1, the majority of GST-
NBD1-R was polyubiquitinated and retained at the top of the
SDS-PAGE gel (Fig. 7A; lanes 1 and 2). This mobility shift was
not observed in the absence of ATP, ubiquitin, E1, or any of the
other components of the Hsp70CHIP E3 complex (31). The
ZFLR mutants Ydj1(C201S) and Ydj1(C162S) both exhibited a
reduced ability to support polyubiquitination of GST-NBD1-R
(Fig. 7B, lanes 3 and 4). A similar defect in polyubiquitination
was observed when Ydj1(I215S) was used in the reaction (Fig.
7B, lane 5), but mutation of other residues in the peptide-bind-
ing pocket had no effect (Fig. 7B, lanes 8–10). Yet, the most
dramatic reduction in Ydj1 activity was observed when ZBDII
and the polypeptide-binding pocket were altered simulta-
neously (Fig. 7B, lanes 6 and 7). Thus, the Ydj1 ZFLR and
peptide-binding pocket cooperate to modulate the confor-
mation of non-native proteins and this synergism is required
to maintain substrates of the Hsp70/CHIP E3 ligase in a
ubiquitination-competent state.
DISCUSSION
Identification of distinct binding sites in the prion Rnq1 for
the Type I Hsp40 Ydj1 and Type II Hsp40 Sis1 explains why
these chaperones play different roles in prion propagation. In
addition, these data support the concept that selective recogni-
tion of substrates by Type I and Type II Hsp40s serve to specify
cytosolic Hsp70 functions (13, 48). Sis1 binding to the non-
prion domain serves to increase the efficiency of [RNQ]
assembly and mediate chaperone-dependent shearing of large
prions into smaller seeds (4, 27). However, if Sis1 is unable to
bind Rnq1, then the ability of Ydj1 to recognize Gln/Asn-rich
regions in the Rnq1 PrD enables it to regulate the [RNQ] prion
pool size.
Sis1 suppresses Rnq1 toxicity by increasing the efficiency of
[RNQ] assembly, which prevents the accumulation of an SDS-
sensitive, toxic off-pathway species (4). Interestingly, the
assembly of the PrD into amyloid-like, SDS-resistant particles
appears more efficient than the assembly of Rnq1 into a similar
species. The PrD is a poor substrate of Sis1, and Ydj1 action is
required for yeast to tolerate PrD overexpression. The toxic
conformer of the PrD is unknown, yet the cell death that occurs
when Ydj1 is inactive correlates with a severalfold increase in
the accumulation of SDS-resistant forms of PrD. Thus, the
toxic species of Rnq1 and its PrD appear different and the ability
of the cell to suppress their accumulation is dependent upon
distinctHsp40s. These data help explainwhyType I andType II
Hsp40s have differential effects in suppressing conformational
disease (49).
Our studies identify the ZFLR, CTD1, and farnesyl moiety as
domains in Type I Hsp40s that are required for modulating the
conformation of non-native proteins. Interestingly, the
requirement of these domains in Ydj1 action is substrate spe-
cific. Mutation of the ZFLR and farnesyl moiety, but not CTD1,
interfered with the ability of Ydj1 to bind the amyloid-like form
of the PrD and Sup35. In contrast, Ydj1 required action of both
the CTD1 and the ZFLR, but not the farnesyl moiety to fold
luciferase. Furthermore, apparent synergy between the ZFLR
and CTD1 enabled Ydj1 to facilitate polyubiquitination of mis-
folded proteins by the quality control E3 ubiquitin ligase CHIP.
Thus, Ydj1 contains at least three regions that facilitate sub-
strate binding and different combinations are utilized to recog-
nize different protein conformers. Through the use of multiple
domains to mediate interaction with non-native substrates,
Ydj1 can cooperate with Hsp70 to facilitate the biogenesis or
degradation of a broad range of substrates. Mutation of hydro-
phobic residues in the peptide-binding site fromType I or Type
IIHsp40s causes defects in cell viability and chaperone function
(46, 50). However, the Ydj1 peptide-binding pocket is not suf-
ficient to perform all its chaperone duties and depending on the
nature of the substrate, it can be dispensable, or its action is
assisted by the ZFLR and/or the C-terminal farnesyl moiety.
Structural data show that the tip of the ZFLR (adjacent to
ZBDII) contains a pair of anti-parallel -strands whose orien-
tation and folding appears to be stabilized by ZBDII (33). Inter-
estingly, the Ydj1 CTD1 is also constructed from anti-parallel
-strands and the co-crystal structure of a Ydj1peptide com-
plex suggests that substrate binding involves formation of an
additional -strand with the two-stranded, anti-parallel
-sheet in the peptide-binding pocket. There are a number of
Gln and Asn side chains exposed on the surface of the anti-
parallel -strands at the tip of the ZFLR. Thus, it is conceivable
that the -strands at the tip of the ZFLR form a -strand with
exposed surfaces of amyloid-like proteins or regions of protein
folding intermediates. Simultaneous binding of substrates to
the ZFLR and CTD1 may then hold the substrate in a confor-
mation that can be recognized by Hsp70.
Models for Type I Hsp40 structure built from small x-ray
scattering data and x-ray crystal structures of Ydj1 fragments
FIGURE 7. Chaperone-dependent polyubiquitination requires the Ydj1
ZFLR and peptide-binding pocket. The role of Ydj1 during in vitro polyubiq-
uitination of a fragment from the CFTR ion channel (NBD-R) was assessed.
GST-NBD1-R (1 M) was incubated with E1 (0.1 M), the E2 UbcH5a (4 M), the
E3 ubiquitin ligase CHIP (3 M), Hsc70 (2 M), plus or minus the indicated form
of Ydj1 (4 M). Polyubiquitinated GST-NBD1-R was retained at the gel front,
whereas unmodified GST-NBD-R resolved at its predicted molecular weight.
Ydj1 Action in Prion Toxicity
FEBRUARY 6, 2009 • VOLUME 284 • NUMBER 6 JOURNAL OF BIOLOGICAL CHEMISTRY 3637
demonstrate that Type I Hsp40s function as homodimers (14).
The ZFLRs in Ydj1 homodimers are located in a central domain
that controls the shape and functional specificity of Ydj1 (13,
14). The requirement for the Type I Hsp40 ZFLR in substrate
binding further explains the functional differences observed
between Type I and Type II Hsp40s (13). Defects in Ydj1 func-
tion caused by mutation of the ZFLR could be due to alteration
of the quaternary structure of Ydj1. However, monomeric
forms of Ydj1 retain the ability to suppress PrD toxicity, so this
is unlikely. Thus, the ZFLR appears to control the quaternary
structure of Type I Hsp40s and can also directly participate in
substrate binding. Additional structural studies are now
required to define the mechanism for ZFLR action in these
processes.
It has been thought for some time that lipid modification of
theC-terminal CAAX box of Type IHsp40s only serves to local-
ize these chaperones to intracellular membranes that include
the endoplasmic reticulum (21, 22). However, large pools of
Ydj1 are cytosolic and it is now clear that farnesylation of Ydj1
enhances its ability to bind cytosolic substrates such the prion
Rnq1. In addition, farnesylation of Ydj1 was recently demon-
strated to be required for proper folding of the kinase Ste11
(51). Interestingly, farnesyl dependent binding of Ydj1 to Ste11
occurs independent of the ZFLR and the peptide-binding
pocket (51). These data are consistent with the model we put
forth that suggests that Type I Hsp40s contain multiple
domains that are capable of participating in the binding of non-
native polypeptides.
The action of a lipidmoiety in polypeptide binding by Ydj1 is
a novel and somewhat surprising finding. Importantly, a num-
ber of humanHsp40s are farnesylated or geranylgeranlyated, so
this mechanism for substrate binding appears to be conserved
(12). The simplest mechanism for farnesyl action in Hsp40
chaperone function is interaction between the farnesyl chain
and hydrophobic surfaces of protein folding intermediates.
However, the farnesyl moiety of Ydj1 could also influence the
conformation of Ydj1 and thereby regulate its substrate speci-
ficity (52).
A point that should be emphasized is that farnesylation of
Ydj1 is critical for biogenesis of some, but not all Ydj1 functions.
Farnesylation of Ydj1 is not required for normal growth of
yeast, but is required for cells to survive heat stress (22). Ydj1
cooperates with Hsp70 and Hsp104 to break up large aggre-
gates (53). In the context of PrD toxicity, it is possible that
farnesylation enables Ydj1 to bind large PrD assemblies and
assist Hsp104 in disaggregation. This activity would help con-
trol the PrD pool size and perhaps suppress PrD toxicity. How-
ever, whereas efficient binding between Ydj1 and the PrD
required farnesylation, the residual Ydj1 interaction appeared
sufficient to control the pool size of SDS-resistant PrD aggre-
gates. In this situation, the cellular threshold to tolerate SDS-
resistant PrD accumulation may be reduced because
Ydj1(C406S) is unable to properly fold other cellular proteins
required for stress protection. For example, Ydj1 is required for
the maturation of numerous kinases implicated in stress
response (54) and farnesylation of Ydj1 is required for proper
folding of at least one kinase (51). Thus, it is conceivable that
reduced stress kinase activity could sensitize yeast that harbor
the non-farnesylated formofYdj1 to PrD toxicitywhen the pool
size of SDS-resistant PrD is not dramatically elevated.
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